Abstract
Background
Short-course radiotherapy is a common treatment for the palliation of painful osseous metastases. Pain flare can be problematic, but its incidence has previously not been well-documented. The objectives of this study were to determine (1) the incidence of pain flare after palliative radiation for painful osseous metastases, and (2) whether single-fraction radiotherapy increases the risk of pain flare.
Materials and methods
Patients accrued to a prospective randomized control trial comparing 8 Gy in one fraction to 20 Gy in five fractions (the Canadian Bone Metastasis Study) were approached to fill out a daily pain and analgesia diary for the 7 days post-radiotherapy. Patients assessed their average pain at the index site using the Present Pain Intensity (PPI) scale of the McGill–Melzack pain questionnaire and recorded their daily analgesic medications, which were translated into an analgesic score. Pain flare was defined as a two-point increase in the PPI with no decrease in analgesic score or a 50% increase in analgesic score with no decrease in PPI on at least two consecutive days.
Results
Forty-seven patients agreed to fill out the diary and 44 (94%) completed it. Fifteen of 44 (34.1%) patients experienced a pain flare that lasted a median of 3 days. Ten of 23 (43.5%) and 5/21 (23.8%) of patients who received 8 Gy and 20 Gy had a pain flare, respectively.
Conclusions
Pain flare is common after palliative radiotherapy for osseous metastases and patients receiving single fraction radiotherapy may be at higher risk. Further study is warranted to determine predictors and preventive interventions.
References
Foley KM (1985) The treatment of cancer pain. New Engl J Med 313:84–94
Malawer MM, Delanet TF (1993) Treatment of metastatic cancer to bone. In: Devita VT, Hellman S, Rosenberg SA (eds) Cancer—principles and practice of oncology. Lippincott, Philadelphia, pp 2225–2244
Hoegler D (1997) Radiotherapy for palliation of symptoms in incurable cancer. Curr Probl Cancer 21:129–183
Wu JSY, Wong R, Johnston M, Bezjak A, Whelan T (2003) On behalf of the Cancer Care Ontario Practice Guidelines Initiative Supportive Care Group. Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys 55:594–605
Price P, Hoskin P, Easton D, Austin D, Palmer SC, Yarnold JR (1986) Prospective randomized trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. Radiother Oncol 6:247–255
Nielsen OS, Bentzen SM, Sandberg E, Gadeberg CC, Timothy AR (1998) Randomized trial of single dose versus fractionated palliative radiotherapy of bone metastases. Radiother Oncol 47:233–240
Steenland E, Leer JW, van Houwelingen H et al (1999) The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study. Radiother Oncol 52:101–109
Koswig S, Budach V (1999) Remineralization and pain relief in bone metastases after different radiotherapy fraction (10 times 3 Gy vs. 1 time 8 Gy). A prospective study (German). Strahlenther Onkol 175:500–508
Kirkbride P, Warde P, Panzarella A et al (2000) A randomized trial comparing the efficacy of single fraction radiation therapy plus ondansetron with fractionated radiation therapy in the palliation of skeletal metastases (abstract). Int J Radiat Oncol Biol Phys 48:185
Gaze MN, Kelly CG, Kerr GR et al (1997) Pain relief and quality of life following radiotherapy for bone metastases: a randomized trial of two fractionation schemes. Radiother Oncol 45:109–116
Cole DJ (1989) A randomized trial of single treatment versus conventional fractionation in the palliative radiotherapy of painful bone metastases. Clin Oncol (R Coll Radiol) 1:59–62
Bone Pain Trial Working Party (1999) 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomized comparison with a multifraction schedule over 12 months of patient follow-up. Radiother Oncol 52:111–121
Melzack R, Torgerson WS (1971) On the language of pain. Anesthesiology 34:50–59
Tannock IF, Osoba D, Stockler MR et al (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14:1756–1764
Chow E, Wu JS, Hoskin P, Coia LR, Bentzen SM, Blitzer PH (2002) International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Radiother Oncol 64:275–280
Chow E, Ling A, Davis L, Panzarella T, Danjoux C (2005) Pain flare following external beam radiotherapy and meaningful change in pain scores in the treatment of bone metastases. Radiother Oncol 75:64–69
Fleiss JL (1981) Statistical methods for rates and proportions. Wiley, New York
Chow E, Wong R, Hruby G et al (2001) Prospective patient-based assessment of effectiveness of palliative radiotherapy for bone metastases. Radiother Oncol 61:77–82
Chow E, Davis L, Holden L et al (2004) A comparison of radiation therapy outcomes of bone metastases employing international consensus endpoints and traditional endpoints. Support Cancer Therapy 1:173–178
Loblaw DA, Bunston T, Bezjak A (1999) Development and testing of a visit—specific patient satisfaction questionnaire: the Princess Margaret Hospital Satisfaction with Doctor Questionnaire (PMH/PSQ-MD). J Clin Oncol 17:1931–1938
Lanciano R, Sherman DM, Michalski J, Preston AJ, Yocom K, Friedman C (2001) The efficacy and safety of once-daily Kytril (granisetron hydrochloride) tablets in the prophylaxis of nausea and emesis following fractionated upper abdominal radiotherapy. Cancer Invest 19:763–772
Franzen L, Nyman J, Hagberg H et al (1996) A randomised placebo controlled study with ondansetron in patients undergoing fractionated radiotherapy. Ann Oncol 7:587–592
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Loblaw, D.A., Wu, J.S., Kirkbride, P. et al. Pain flare in patients with bone metastases after palliative radiotherapy—a nested randomized control trial. Support Care Cancer 15, 451–455 (2007). https://doi.org/10.1007/s00520-006-0166-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-006-0166-y